133 related articles for article (PubMed ID: 6509453)
1. High-dose etoposide for refractory malignancies: a phase I study.
Postmus PE; Mulder NH; Sleijfer DT; Meinesz AF; Vriesendorp R; de Vries EG
Cancer Treat Rep; 1984 Dec; 68(12):1471-4. PubMed ID: 6509453
[TBL] [Abstract][Full Text] [Related]
2. [Clinical trial of high-dose etoposide].
Yoshida T; Nakazumi Y; Kanno M; Kobayashi K; Ito K; Kondo K; Kanamori K; Nakamura S; Matsuda T
Gan To Kagaku Ryoho; 1988 Mar; 15(3):469-74. PubMed ID: 2831820
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of high-dose etoposide phosphate in man.
Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies.
Murren JR; DiStasio SA; Lorico A; McKeon A; Zuhowski EG; Egorin MJ; Sartorelli AC; Rappa G
Cancer J; 2000; 6(4):256-65. PubMed ID: 11038146
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report.
Chard RL; Krivit W; Bleyer WA; Hammond D
Cancer Treat Rep; 1979; 63(11-12):1755-9. PubMed ID: 294306
[TBL] [Abstract][Full Text] [Related]
9. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.
Wolff SN; Fer MF; McKay CM; Hande KR; Hainsworth JD; Greco FA
J Clin Oncol; 1983 Nov; 1(11):701-5. PubMed ID: 6366131
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ
Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029
[TBL] [Abstract][Full Text] [Related]
11. High-dose teniposide for refractory malignancies: a phase I study.
de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
[TBL] [Abstract][Full Text] [Related]
12. [Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].
Suzuki K
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2772-9. PubMed ID: 3753024
[TBL] [Abstract][Full Text] [Related]
13. Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors.
Broun ER; Nichols CR; Mandanas R; Salzman D; Turns M; Hromas R; Cornetta K; Einhorn LH
Bone Marrow Transplant; 1995 Sep; 16(3):353-8. PubMed ID: 8535306
[TBL] [Abstract][Full Text] [Related]
14. High-dose etoposide in the treatment of relapsed primary brain tumors.
Finn GP; Bozek T; Souhami RL; Slevin ML; Thomas DG
Cancer Treat Rep; 1985 Jun; 69(6):603-5. PubMed ID: 4016766
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
Bunn PA; Kelly K
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-144-S12-148. PubMed ID: 9331140
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion.
Lokich J; Corkery J
Cancer Treat Rep; 1981; 65(9-10):887-9. PubMed ID: 7273024
[TBL] [Abstract][Full Text] [Related]
18. High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.
Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; McCauley M; Mazanet R; Schnipper L; Frei E; Antman KH
Semin Oncol; 1994 Oct; 21(5 Suppl 12):83-5. PubMed ID: 7992072
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
[TBL] [Abstract][Full Text] [Related]
20. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]